Stock comparison

MRKvsPFE

Merck & Co IncvsPfizer Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

MRK

Merck & Co Inc

$114.62

+15.57%

Pharmaceuticals$298.8BNYSE
PFE

Pfizer Inc

$26.67

+3.17%

Pharmaceuticals$155.1BNYSE

60-day price, rebased to 100

MRK +1.10% · PFE +3.13%

Round-by-round

MRK 3·PFE 3
EdgePFE

Valuation upside

-26.90% vs -18.10% to DCF fair value

EdgeMRK

Balance-sheet strength

Altman Z 4.02 vs 2.15

EdgePFE

Fundamental quality

Piotroski 4.00 vs 6.00 (of 9)

EdgeMRK

Growth + margins

Rule-of-40 20.30 vs 12.90

EdgePFE

60-day momentum

+1.10% vs +3.13% price return

EdgeMRK

Market-cap liquidity

$298.8B vs $155.1B

Verdict

Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onMRKorPFE

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.

For informational and educational purposes only. Not financial advice. Learn more